Recent Advances in the Pharmacotherapy of Schizophrenia

References

• Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 1983; 6: S9–26, (suppl 1)
   PubMed Web of Science ®Google Scholar
• Van Putten T, May P RA, Marder S R. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41: 1036–9
   PubMed Web of Science ®Google Scholar
• Weiden P J, Mann J J, Haas G, Mattson M, Frances A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987; 144: 1148–53
   PubMed Web of Science ®Google Scholar
• Casey D E. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Schizophrenia, S R Hirsch, D R Weinberger. Blackwell Scientific, CambridgeEngland 1995; 546–65
   Google Scholar
• Kane J M. Treatment of schizophrenia. Schizophr Bull 1987; 13: 133–56
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96
   PubMed Web of Science ®Google Scholar
• Ram R, Bromet E J, Eaton W W, Pato C, Schwartz J E. The natural course of schizophrenia: a review of first admission studies. Schizophr Bull 1992; 18: 185–207
   PubMed Web of Science ®Google Scholar
• Gaebel W, Pietzcker A. One-year outcome of schizophrenic patients—the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 1985; 18: 235–9
   PubMed Web of Science ®Google Scholar
• McGlashan T H, Fenton W S. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 1993; 19: 71–84
   PubMed Web of Science ®Google Scholar
• Wyatt R W. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325–51
   PubMed Web of Science ®Google Scholar
• Addington D E, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26
   PubMed Web of Science ®Google Scholar
• Breier A, Buchanan R W, Irish D, Carpenter W T, Jr. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44: 1145–9
   PubMedGoogle Scholar
• Green A I, Schildkraut J J. Should clozapine be a first-line treatment for schizophrenia: the rationale for a double-blind clinical trial in first-episode patients. Harvard Rev Psychiatry 1995; 3: 1–9
   PubMed Web of Science ®Google Scholar
• Meltzer H Y, Cola P, Way L, Thompson P A, Bastani B, Davies M A, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630–8
   PubMed Web of Science ®Google Scholar
• Goff D C. Have the serotonin-dopamine antagonists rendered traditional antipsychotic agents obsolete?. Harvard Rev Psychiatry 1995; 3: 101–3
   Web of Science ®Google Scholar
• Lindström L H. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand 1994; 89: 74–6, (suppl 380)
   Google Scholar
• Fitton A, Heel R C. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990; 40: 722–47
   PubMed Web of Science ®Google Scholar
• Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47: 52–6
   PubMed Web of Science ®Google Scholar
• Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995; 345: 557–62
   PubMed Web of Science ®Google Scholar
• Goldstein J M. Preclinical tests that predict clozapine-like atypical antipsychotic actions. Critical issues in the treatment of schizophrenia, N Brunello, G Racagni, S Z Langer, J Mendlewicz. Karger, Basel 1995; 95–101
   Google Scholar
• Goldstein J M. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 1995; 4: 291–8
   Google Scholar
• Helmchen H. Clinical experience with clozapine in Germany. Psychopharmacology 1989; 99: S80–3, (suppl)
   PubMedGoogle Scholar
• Claghorn J, Honigfeld G, Abuzzahab F, Sr, Wang R, Steinbook R, Tuason V, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377–8
   PubMed Web of Science ®Google Scholar
• Pickar D, Owen R R, Litman R E, Konicki E, Gutierrez R, Rapaport H M. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49: 345–53
   PubMed Web of Science ®Google Scholar
• Overall J E, Gorham D R. Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812
   Web of Science ®Google Scholar
• Andreasen N. Modified scale for the assessment of negative symptoms. NIMH treatment strategies in schizophrenia study. Public Health Administration, Department of Health and Human Services, Rockville, Maryland 1984
   Google Scholar
• Paunovic V R, Marinkovic D, Timotijevic I, Jaovic-Gasic M. Clozapine in the treatment of negative syndrome in schizophrenia: a three-year follow-up study. Presented at the 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum, KyotoJapan, 1990
   Google Scholar
• Lindenmayer J P, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment refractory schizophrenics. J Clin Psychopharmacol 1994; 14: 201–4
   PubMed Web of Science ®Google Scholar
• Breier A, Buchanan R W, Kirkpatrick B, Davis O R, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20–6
   PubMed Web of Science ®Google Scholar
• Carpenter W T, Jr, Conley R R, Buchanan R W, Breier A, Tamminga C A. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152: 827–32
   PubMed Web of Science ®Google Scholar
• Meltzer H Y, Lee M A, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand Suppl 1994; 384: 95–101
   PubMedGoogle Scholar
• Buchanan R W, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36: 717–25
   PubMed Web of Science ®Google Scholar
• Lee M A, Thompson P A, Meltzer H Y. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994; 55: 82–7
   PubMed Web of Science ®Google Scholar
• Goldberg T E, Weinberger D R. The effects of clozapine on neurocognition: an overview. J Clin Psychiatry 1994; 55: 88–90
   Google Scholar
• Kane J M, Honigfeld G, Singer J, Meltzer H Y. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96
   PubMed Web of Science ®Google Scholar
• Miller D D, Perry P J, Cadoret R J, Andreasen N C. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35: 8–15
   PubMed Web of Science ®Google Scholar
• Lieberman J A, Safferman A Z, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744–52
   PubMed Web of Science ®Google Scholar
• Casey D E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: S47–53, (suppl)
   PubMed Web of Science ®Google Scholar
• Lieberman J A, Saltz B L, Johns C A, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10
   PubMed Web of Science ®Google Scholar
• De Leon J, Verghese C, Stanilla J K, Lawrence T, Simpson G M. Treatment of polydipsia and hyponatremia in psychiatric patients: can clozapine be a new option?. Neuropsychopharmacology 1995; 12: 133–8
   Google Scholar
• Meltzer H Y, Goode D J, Schyve P M, Young M, Fang V S. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979; 136: 1550–5
   PubMed Web of Science ®Google Scholar
• Meltzer H Y. The mechanism of action of clozapine in relation to its clinical advantages. Novel antipsychotic drugs, H Y Meltzer. Raven, New York 1992; 1–13
   Google Scholar
• Alvir J M, Lieberman J A, Safferman A Z, Schwimmer J L, Schaaf J A. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7
   PubMed Web of Science ®Google Scholar
• Toth P, Frankenburg F R. Clozapine and seizures: a review. Can J Psychiatry 1994; 39: 236–8
   PubMed Web of Science ®Google Scholar
• Pacia S V, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44: 2247–9
   PubMed Web of Science ®Google Scholar
• Devinsky O, Pacia S V. Seizures during clozapine therapy. J Clin Psychiatry 1994; 55: 153–6, (suppl B)
   PubMed Web of Science ®Google Scholar
• Kane J M, Marder S R. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19: 287–302
   PubMed Web of Science ®Google Scholar
• Meltzer H Y, Cola P A. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994; 55: 161–5, (suppl B)
   PubMed Web of Science ®Google Scholar
• Meltzer H Y, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183–90
   PubMed Web of Science ®Google Scholar
• Meltzer H Y. Clozapine: is another view valid?. Am J Psychiatry 1995; 152: 821–5
   PubMed Web of Science ®Google Scholar
• Janssen P AJ, Niemegeers C JE, Awouters F, Schellekens K HL, Megens A AHP, Meert T F. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonist properties. J Pharmacol Exp Ther 1988; 244: 685–93
   PubMed Web of Science ®Google Scholar
• Leysen J E, Janssen P M, Gommeren W, Wynants J, Pauwels P J, Janssen P A. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992; 41: 494–508
   PubMed Web of Science ®Google Scholar
• Moore N A, Calligaro D O, Wong D T, Bymaster F, Tye N C. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993; 2: 281–93
   Google Scholar
• Seeger T F, Seymour P A, Schmidt A W, Zorn S H, Schulz D W, Lebel L A, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–13
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993; 38: S80–8, (suppl 3)
   PubMed Web of Science ®Google Scholar
• Migler B M, Warawa E J, Malick J B. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 1993; 112: 299–307
   PubMedGoogle Scholar
• Goldstein J M, Snyder D H. Effects of Seroquel™, clozapine, and other putative atypical antipsychotic agents in primate models of dystonia [Abstract]. Schizophr Res 1995; 15: 152
   Web of Science ®Google Scholar
• Hoenicke E M, Vanecek S A, Woods J H. The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. J Pharmacol Exp Ther 1992; 263: 276–84
   Google Scholar
• Borison R L, Diamond B I, Pathiraja A P, Meibach R C. Clinical overview of risperidone. Novel antipsychotic drugs, H Y Meltzer. Raven, New York 1992; 233–9
   Google Scholar
• Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan G W, et al. A Canadian multicenter placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40
   PubMed Web of Science ®Google Scholar
• Marder S R, Meibach R C. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35
   PubMed Web of Science ®Google Scholar
• Möller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992; 15: 90A–1A, (suppl 1, part A)
   Google Scholar
• Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology 1989; 99: 445–9
   PubMed Web of Science ®Google Scholar
• Høyberg O J, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88: 395–402
   PubMed Web of Science ®Google Scholar
• Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 129–37
   PubMed Web of Science ®Google Scholar
• Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 207–13
   PubMed Web of Science ®Google Scholar
• Möller H J, Muller H, Borison R L, Schooler N R, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245: 45–9
   PubMed Web of Science ®Google Scholar
• Daniel D G, Goldberg T E, Weinberger D R, Kleinman J E, Pickar D, Lubick L J, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996; 153: 417–9
   PubMedGoogle Scholar
• Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15: 36S–44S, (1 suppl 1)
   PubMed Web of Science ®Google Scholar
• Huang M L, Van Peer A, Woestenborgha R, De Coster R, Heykants J, Jansen A A, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257–68
   PubMed Web of Science ®Google Scholar
• Bersani G, Bressa G M, Meco G, Marini S, Pozzi F. Combined serotonin-5-HT2 and dopamine-D2 antagonism in schizophrenia: clinical, extrapyramidal, and neuroendocrine response in a preliminary study with risperidone (R64766). Hum Psychopharmacol 1990; 5: 225–31
   Google Scholar
• Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295–305
   PubMed Web of Science ®Google Scholar
• Borison R L, Pathiraja A P, Diamond B I, Meibach R C. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28: 213–8
   PubMed Web of Science ®Google Scholar
• Moore N A, Tye N C, Axton M S, Risius F C. The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 1992; 262: 545–51
   PubMed Web of Science ®Google Scholar
• Bymaster F P, Calligaro D O, Falcone J F, Marsh R D, Moore N A, Tye N C, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87–96
   PubMed Web of Science ®Google Scholar
• Fuller R W, Snoddy H D. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 1992; 77: 87–93
   Google Scholar
• Stockton M E, Rasmussen K. A comparison of olanzapine and clozapine effects on dopamine neuronal activity [Abstract]. Soc Neurosci Abstr 1993; 19: 383
   Google Scholar
• Stockton M E, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996; 14: 97–104
   PubMed Web of Science ®Google Scholar
• Beasley C M, Montgomery S, Tye N C. Olanzapine: an openlabel study in schizophrenia. Presented at the 2nd International Conference on Schizophrenia, Vancouver, British Columbia, 1992
   Google Scholar
• Beasley C M, Tollefson G, Tye N C, et al. Olanzapine: a potential “atypical” antipsychotic agent. Presented at the 32nd annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1993
   Google Scholar
• Tran P V, Beasley C M, Dellva M A, Cousins L M, Gusman S T, Tollefson G D. Long-term efficacy and safety of olanzapine. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• Beasley C M, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159–67
   PubMed Web of Science ®Google Scholar
• Beasley C M, Tran P V, Tamura R N, Sanger T M, Tollefson G D. Olanzapine versus haloperidol: results of the multi-center international trial. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• CGI, Clinical Global Impression. ECDEU assessment manual for psychopharmacology. Revised ed., W Guy. US Department of Health, Education, and Welfare, Rockville, Maryland 1976; 218–22
   Google Scholar
• Kay S R, Opler L A, Lindenmayer J P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 1989; 155: 59–65, (suppl 7)
   Google Scholar
• Street J S, Tamura R N, Sanger T M, Tollefson G D. A comparison of the incidence of long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• Beasley C M, Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–23
   PubMed Web of Science ®Google Scholar
• Skarsfeldt T, Perregaard J. Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur J Pharmacol 1990; 182: 613–4
   PubMed Web of Science ®Google Scholar
• Hyttel J, Nielsen J B, Nowak G. The acute effect of sertindole on brain 5-HT2, D2 and α1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sec 1992; 89: 61–9
   PubMed Web of Science ®Google Scholar
• Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembol H L, Meier E, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991; 22: 239–50
   Web of Science ®Google Scholar
• Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 1992; 10: 25–33
   PubMed Web of Science ®Google Scholar
• Targum S, Caputo K, Grebb J, Chung L, Kashkin K, Mendels J. Sertindole treatment of hospitalised schizophrenic patients. Presented at the 1st International Congress on Hormones, Brain, and Neuropsychopharmacology, RhodesGreece, 1993
   Google Scholar
• Barnes T RE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6
   PubMed Web of Science ®Google Scholar
• Mack R, Zborowski J, Morris D, Sebree T, Wallin B. Efficacy, safety, and dose response of three doses of sertindole and three doses of Haldol in schizophrenic patients. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• Simpson G M, Angus J WS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 45: 11–9, (suppl 212)
   Google Scholar
• AIMS: Abnormal Involuntary Movement Scale. ECDEU assessment manual for psychopharmacology. Revised ed., W Guy. US Department of Health, Education, and Welfare, Rockville, Maryland 1976; 534–5
   Google Scholar
• Daniel D, Targum S, Zimbroff D, Mack R, Zborowski J, Morris D, et al. Efficacy and safety: dose responses of three doses of sertindole and three doses of haloperidol in schizophrenic patients. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• Van Kammen D P, McEvoy J P, Targum S D, Kardatzke D, Sebree T B, Sertindole Study Group. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168–75
   PubMed Web of Science ®Google Scholar
• Van Kammen D, Holgate K L, Sebree T, Zborowski J, Schmitz P, Wallin B. Two open-label studies of sertindole. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• Saller C F, Salama A L. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 285–92
   PubMed Web of Science ®Google Scholar
• Goldstein J M, Litwin L C, Sutton E B, Malick J B. Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 293–8
   PubMed Web of Science ®Google Scholar
• Goldstein J M. The profile of “Seroquel” in preclinical tests for antipsychotic atypicality. Presented at the 3rd International Conference on Schizophrenia, Vancouver, British Columbia, 1994
   Google Scholar
• Malick J B. 5-HT2/D2 receptor antagonists—novel atypical antipsychotics. Schizophrenia: new developments in its understanding and treatment. Presented at the International Business Communications Conference on Schizophrenia, London, 1992
   Google Scholar
• Meltzer H Y. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55: 47–52
   PubMed Web of Science ®Google Scholar
• Ellenbroek B A, Willemen A, Cools A R. Are antagonists of the dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia: a pilot study in Java monkeys. Neuropsychopharmacology 1991; 2: 191–9
   Web of Science ®Google Scholar
• Fabre L F, Arvanitis L, Pultz J, Jones V M, Malick J B, Slotnick V B. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995; 17: 366–78
   PubMed Web of Science ®Google Scholar
• Fabre L F. A multicenter, open, pilot trial of ICI 204,636 in hospitalized patients with acute psychotic symptomatology. Presented at the 4th International Congress on Schizophrenia Research, Colorado Springs, Colorado, 1993
   Google Scholar
• Borison R L, Arvanitis L A, Miller B G, US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16: 158–69
   PubMed Web of Science ®Google Scholar
• Hirsch S, Arvanitis L A, Miller B G, Smith A, Seroquel Study Group. A multicentre, double-blind, placebo-controlled comparison of low and high dosage regimens of ‘Seroquel’ in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia [Abstract]. Eur Neuropsychopharmacol 1994; 4: 384–5, (3 spec iss)
   Google Scholar
• Hamner M B, Arvanitis L A, Miller B G, Link C GG, Hong W W. Lack of sustained elevation of plasma prolactin in schizophrenic patients treated with ICI 204,636 (Seroquel™). Presented at the 148th annual meeting of the American Psychiatric Association, Miami, Florida, 1995
   Google Scholar
• Hamner M B, Arvanitis L A, Miller B E, Link C GG, Hong W. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996; 32: 107–10
   PubMed Web of Science ®Google Scholar
• Link C, Smith A, Miller B, Ryan J, Seroquel Study Group. A multicentre, double-blind controlled comparison of Seroquel and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia [Abstract]. Neuropsychopharmacology 1994; 4: 385, (3 spec iss)
   Google Scholar
• Fleischhacker W W, Link C G. A multicenter, double-blind, randomised comparison of dose and dose regimen of “Seroquel” in the treatment of patients with schizophrenia. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• Arvanitis L. Seroquel (ICI 204,636), a new “atypical” antipsychotic: overview of clinical development. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• Hong W W, Arvanitis L A. The atypical profile of Seroquel (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• Howard H R, Prakash C, Seeger T F. Ziprasidone hydrochloride. Drugs Future 1994; 19: 560–3
   Google Scholar
• Heym J, Seeger T, Seymour P, Howard H, Smolarek T, Tremaine L. Pharmacology and phase I evaluation of CP-88,059: a combined antagonist of 5HT2 and D2 receptors with atypical antipsychotic potential. Presented at the 31st annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1992
   Google Scholar
• Meltzer H Y, Matsubara S, Lee J C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238–46
   PubMed Web of Science ®Google Scholar
• Seeger T F, Schmidt A W, Lebel L A, Koe B K, Zorn S H, Schulz D W, et al. CP88,059: a new antipsychotic with mixed dopamine D2 and serotonin 5-HT2 antagonist activities [Abstract]. Soc Neurosci Abstr 1993; 19: 1623
   Google Scholar
• Zorn S H, Morrone J, Seeger T F, Jackson E, Johnson C, Lebel L A, et al. The antipsychotic drug CP-88,059 is an antagonist at both 5HT2 and 5HT1C receptors [Abstract]. Soc Neurosci Abstr 1993; 19: 599
   Google Scholar
• Canton H, Verrièle L, Colpaert F C. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HTIC sites. Eur J Pharmacol 1990; 191: 93–6
   PubMed Web of Science ®Google Scholar
• Wander T J, Nelson A, Okazaki H, Richelson E. Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol 1987; 143: 279–82
   PubMed Web of Science ®Google Scholar
• Mason S L, Reynolds G P. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol 1992; 221: 397–8
   PubMed Web of Science ®Google Scholar
• Howard H R. Design and synthesis of the atypical antipsychotic agent CP-88,059. Presented at the 209th national meeting of the American Chemical Society, Chicago, Illinois, 1993
   Google Scholar
• Seymour P A, Seeger T F, Guanowsky V, Robinson G L, Howard H, Heym J. Behavioral pharmacology of CP-88,059: a new antipsychotic with both 5-HT2 and D2 antagonist activities [Abstract]. Soc Neurosci Abstr 1993; 19: 599
   Google Scholar
• Bench C J, Lammertsma A A, Dolan R J, Grasby P M, Warrington S J, Gunn K, et al. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059–01: a study using positron emission tomography and 11C-raclopride. Psychopharmacology 1993; 112: 308–14
   PubMed Web of Science ®Google Scholar
• Harrigan E, Chandler L P, Ko G. Ziprasidone: a novel antipsychotic. Presented at the 34th annual meeting of the American College of Psychopharmacology, San Juan, Puerto Rico, 1995
   Google Scholar
• Niemegeers C J, Janssen P A. A systemic study of the pharmacological activities of dopamine antagonists. Life Sci 1979; 24: 2201–15
   Google Scholar
• Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982; 51: 321–9
   PubMedGoogle Scholar
• Lucki I, Nobler M S, Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 1984; 228: 133–9
   PubMed Web of Science ®Google Scholar
• Meert T F, Niemegeers C J, Awouters F, Janssen P A. Partial and complete blockade of 5-hydroxytryptophan (5-HTP)-induced head twitches in the rat: a study of ritanserin (R55667), risperidone (R64766), and related compounds. Drug Dev Res 1989; 13: 237–44
   Google Scholar
• Meltzer H Y. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 1992; 17: 22–9, (suppl)
   Google Scholar
• White F J, Wang R Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983; 221: 1054–7
   PubMed Web of Science ®Google Scholar
• Coward D M. General pharmacology of clozapine. Br J Psychiatry 1992; 17: 5–11, (suppl)
   Google Scholar
• Casey D E, Gerlach J, Christensson E. Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology 1980; 70: 83–7
   PubMed Web of Science ®Google Scholar
• Spealman R D, Katz J L. Some effects of clozapine on punished responding by mice and squirrel monkeys. J Pharmacol Exp Ther 1980; 212: 435–40
   PubMedGoogle Scholar
• Tye N C, Iversen S D, Green A R. The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 1979; 18: 689–95
   PubMed Web of Science ®Google Scholar
• Nielsen E B. Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 1988; 94: 115–8
   Google Scholar